《業績》可口可樂(KO.US)上季多賺58%勝預期 歐洲需求強勁抵銷其他地區疲軟
可口可樂(KO.US)第二季純利按年增58%至38.1億美元,調整後每股盈利為87美仙,高於預期的83美仙。營收增1%至126.2億美元,略高於預期的125.4億美元。
可口可樂上季全球單位箱銷量下降1%。除歐洲、中東和非洲業務增長3%外,所有部門銷量均出現下滑。北美可口可樂銷量跌1%,拉丁美洲跌2%,亞太市場區銷售跌3%。
可口可樂亦宣布,計劃今年秋季在美國推出以蔗糖製成的可口可樂。
公司將全年每股可比收益增長預期下調至3%,為先前預期區間的上限。該公司重申其盈利預測,今年收入自然增長率將達5%至6%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.